MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

Search

Grifols SA

Geschlossen

BrancheFinanzen

8.408 0.17

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.344

Max

8.704

Schlüsselkennzahlen

By Trading Economics

Einkommen

17M

69M

Verkäufe

183M

2B

KGV

Branchendurchschnitt

45.229

22.015

EPS

0.101

Gewinnspanne

3.491

Angestellte

23,833

EBITDA

57M

482M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+72.24% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3.3B

6.8B

Vorheriger Eröffnungskurs

8.24

Vorheriger Schlusskurs

8.408

Nachrichtenstimmung

By Acuity

20%

80%

38 / 542 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

Grifols SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Apr. 2025, 17:19 UTC

Akquisitionen, Fusionen, Übernahmen

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2. Apr. 2025, 13:02 UTC

Akquisitionen, Fusionen, Übernahmen

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2. Apr. 2025, 10:13 UTC

Akquisitionen, Fusionen, Übernahmen

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8. Juli 2024, 10:40 UTC

Akquisitionen, Fusionen, Übernahmen

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8. Juli 2024, 09:13 UTC

Akquisitionen, Fusionen, Übernahmen

Grifols Faces Delisting Bid From Founding Family and Brookfield

2. Apr. 2025, 09:27 UTC

Heiße Aktien

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Peer-Vergleich

Kursveränderung

Grifols SA Prognose

Kursziel

By TipRanks

72.24% Vorteil

12-Monats-Prognose

Durchschnitt 14.02 EUR  72.24%

Hoch 19.05 EUR

Tief 11 EUR

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Grifols SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

8.152 / 8.574Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

38 / 542 Ranking in Finanzen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.